Leiden-based medtech outfit Livassured and its Nightwatch epilepsy monitor will become part of Sweden’s Abilia, a leading provider of assistive technology solutions in Scandinavia and Europe. The acquisition creates new opportunities for international expansion. With Abilia’s established market presence and expertise, Livassured will be able to accelerate its growth and ensure more people with epilepsy and their caregivers benefit from reliable seizure detection.
Livassured was founded from a Dutch research consortium with the mission to develop Nightwatch, a clinically validated seizure monitor designed to detect severe epileptic seizures during sleep. Since its market introduction in 2018 (link in Dutch), the device has had a significant positive impact across the epilepsy community in Europe, supporting patients, caregivers and healthcare professionals with reliable detection and real-time alerts. Today, the system is used by thousands of families and care institutions and has proven its value in both daily life and clinical practice.
Headquartered in Solna, Sweden, Abilia has decades of experience developing and providing assistive technology in areas such as cognition, communication, environmental control and alarms. Its solutions are built on evidence and close collaboration with healthcare professionals to empower people with special needs to live more independent lives. The company is part of the publicly listed Swedish medtech investor Medcap.
